A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

141

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

August 1, 2039

Study Completion Date

August 1, 2041

Conditions

Select Advanced Solid Tumors

Interventions

DRUG

Cyclophosphamide

Given by IV

DRUG

Fludarabine

Given by IV

DRUG

KSQ-004EX

Given by IV

DRUG

Interleukin-2

Given by IV

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston